查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1386403

皮膚癌診斷與治療市場報告：2030 年趨勢、預測與競爭分析

Skin Cancer Diagnostics & Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

皮膚癌診斷和治療的趨勢和預測

預計到2030年，全球皮膚癌診斷和治療市場將達到181億美元，2024年至2030年年複合成長率為5.0%。市場的主要促進因素是政府加強早期檢測和皮膚癌治療的舉措、活性化皮膚癌診斷和治療的研發活動以及全球皮膚癌盛行率的增加。這與提高意識有關。全球皮膚癌診斷和治療市場前景廣闊，診斷和治療市場充滿機會。

皮膚癌診斷與治療市場洞察

Lucintel 預測，由於非黑色素瘤病例數量不斷增加，預計在預測期內非黑色素瘤將出現高速成長。這些皮膚癌始於皮膚細胞，癌變（惡性）的癌細胞可以生長並破壞附近的組織。

治療仍然是該市場最大的部分。

由於北美皮膚癌的盛行率和發生率不斷增加，在預測期內它可能仍然是最大的部分。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2. 未來哪個細分市場成長較快？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和業務風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球皮膚癌診斷與治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球皮膚癌診斷與治療市場趨勢（2018-2023）與預測（2024-2030）
  • 按癌症類型分類的全球皮膚癌診斷和治療市場
    • 黑色素瘤
    • 非黑色素瘤
  • 按類型分類的全球皮膚癌診斷和治療市場
    • 診斷
    • 治療
    • 其他

第4章 2018-2030年分地區市場趨勢及預測分析

  • 全球皮膚癌診斷與治療市場（按地區）
  • 北美皮膚癌診斷與治療市場
  • 歐洲皮膚癌診斷與治療市場
  • 亞太皮膚癌診斷與治療市場
  • 其他區域皮膚癌診斷與治療市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按癌症類型分類的全球皮膚癌診斷和治療市場成長機會
    • 全球皮膚癌診斷和治療市場成長機會（按類型）
    • 按地區分類的全球皮膚癌診斷和治療市場成長機會
  • 全球皮膚癌診斷和治療市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球皮膚癌診斷和治療市場的能力
    • 全球皮膚收購和合資
    • 認證和許可

第7章 主要企業概況

  • AB Science
  • Abbott Laboratories
  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Castle Biosciences
  • Daiichi Sankyo
  • DAMAE Medical
  • DermTech
  • F. Hoffmann-La Roche
簡介目錄

Skin Cancer Diagnostics & Therapeutics Trends and Forecast

The future of the global skin cancer diagnostics & therapeutics market looks promising with opportunities in the diagnosis and therapeutic markets. The global skin cancer diagnostics & therapeutics market is expected to reach an estimated $18.1 billion by 2030 with a CAGR of 5.0% from 2024 to 2030. The major drivers for this market are increasing government initiatives for early detection and skin cancer treatment, rising research and development activities for skin cancer diagnostics and therapeutics, and growing incidences and rising awareness of skin cancer globally.

A more than 150-page report is developed to help in your business decisions.

Skin Cancer Diagnostics & Therapeutics by Segment

The study includes a forecast for the global skin cancer diagnostics & therapeutics by cancer type, type, and region.

Skin Cancer Diagnostics & Therapeutics Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Melanoma
  • Non-Melanoma

Skin Cancer Diagnostics & Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Diagnosis
  • Therapeutics
  • Others

Skin Cancer Diagnostics & Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Skin Cancer Diagnostics & Therapeutics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies skin cancer diagnostics & therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the skin cancer diagnostics & therapeutics companies profiled in this report include-

  • Ab Science
  • Abbott Laboratories
  • Amgen
  • Astrazeneca
  • Bristol-Myers Squibb
  • Castle Biosciences
  • Daiichi Sankyo
  • Damae Medical
  • Dermtech
  • F. Hoffmann-La Roche

Skin Cancer Diagnostics & Therapeutics Market Insights

Lucintel forecasts that non-melanoma is expected to witness higher growth over the forecast period due to growing the increasing cases of non-melanoma as these skin cancer starts in skin cells and a cancerous (malignant) growth is a group of cancer cells that can grow into and destroy nearby tissue. it can also spread (metastasize) to other parts of the body, but this is rare with non-melanoma skin cancer.

Within this market, therapeutic will remain the largest segment.

North America will remain the largest segment over the forecast period due to the growing prevalence and incidence of skin cancers in this region.

Features of the Global Skin Cancer Diagnostics & Therapeutics Market

Market Size Estimates: Skin cancer diagnostics & therapeutics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Skin cancer diagnostics & therapeutics market size by cancer type, type, and region in terms of value ($B).

Regional Analysis: Skin cancer diagnostics & therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different cancer types, types, and regions for the skin cancer diagnostics & therapeutics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the skin cancer diagnostics & therapeutics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the skin cancer diagnostics & therapeutics market size?

Answer: The global skin cancer diagnostics & therapeutics market is expected to reach an estimated $18.1 billion by 2030.

Q.2 What is the growth forecast for skin cancer diagnostics & therapeutics market?

Answer: The global skin cancer diagnostics & therapeutics market is expected to grow with a cagr of 5.0% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the skin cancer diagnostics & therapeutics market?

Answer: The major drivers for this market are increasing government initiatives for early detection and skin cancer treatment, rising research and development activities for skin cancer diagnostics and therapeutics, and growing incidences and rising awareness of skin cancer globally.

Q4. What are the major segments for skin cancer diagnostics & therapeutics market?

Answer: The future of the skin cancer diagnostics & therapeutics market looks promising with opportunities in the diagnosis and therapeutic markets.

Q5. Who are the key skin cancer diagnostics & therapeutics market companies?

Answer: Some of the key skin cancer diagnostics & therapeutics companies are as follows:

  • AB Science
  • Abbott Laboratories
  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Castle Biosciences
  • Daiichi Sankyo
  • DAMAE Medical
  • DermTech
  • F. Hoffmann-La Roche

Q6. Which skin cancer diagnostics & therapeutics market segment will be the largest in future?

Answer: Lucintel forecasts that non-melanoma is expected to witness higher growth over the forecast period due to growing the increasing cases of non-melanoma as these skin cancer starts in skin cells and a cancerous (malignant) growth is a group of cancer cells that can grow into and destroy nearby tissue. it can also spread (metastasize) to other parts of the body, but this is rare with non-melanoma skin cancer.

Q7. In skin cancer diagnostics & therapeutics market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to the growing prevalence and incidence of skin cancers in this region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the skin cancer diagnostics & therapeutics market by cancer type (melanoma and non-melanoma), type (diagnosis, therapeutics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Skin Cancer Diagnostics & Therapeutics Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Skin Cancer Diagnostics & Therapeutics Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Skin Cancer Diagnostics & Therapeutics Market by Cancer Type
    • 3.3.1: Melanoma
    • 3.3.2: Non-melanoma
  • 3.4: Global Skin Cancer Diagnostics & Therapeutics Market by Type
    • 3.4.1: Diagnosis
    • 3.4.2: Therapeutics
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Skin Cancer Diagnostics & Therapeutics Market by Region
  • 4.2: North American Skin Cancer Diagnostics & Therapeutics Market
    • 4.2.2: North American Skin Cancer Diagnostics & Therapeutics Market by Type: Diagnosis, Therapeutics, and Others
  • 4.3: European Skin Cancer Diagnostics & Therapeutics Market
    • 4.3.1: European Skin Cancer Diagnostics & Therapeutics Market by Cancer Type: Melanoma and Non-melanoma
    • 4.3.2: European Skin Cancer Diagnostics & Therapeutics Market by Type: Diagnosis, Therapeutics, and Others
  • 4.4: APAC Skin Cancer Diagnostics & Therapeutics Market
    • 4.4.1: APAC Skin Cancer Diagnostics & Therapeutics Market by Cancer Type: Melanoma and Non-melanoma
    • 4.4.2: APAC Skin Cancer Diagnostics & Therapeutics Market by Type: Diagnosis, Therapeutics, and Others
  • 4.5: ROW Skin Cancer Diagnostics & Therapeutics Market
    • 4.5.1: ROW Skin Cancer Diagnostics & Therapeutics Market by Cancer Type: Melanoma and Non-melanoma
    • 4.5.2: ROW Skin Cancer Diagnostics & Therapeutics Market by Type: Diagnosis, Therapeutics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Skin Cancer Diagnostics & Therapeutics Market by Cancer Type
    • 6.1.2: Growth Opportunities for the Global Skin Cancer Diagnostics & Therapeutics Market by Type
    • 6.1.3: Growth Opportunities for the Global Skin Cancer Diagnostics & Therapeutics Market by Region
  • 6.2: Emerging Trends in the Global Skin Cancer Diagnostics & Therapeutics Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Skin Cancer Diagnostics & Therapeutics Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Skin Cancer Diagnostics & Therapeutics Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: AB Science
  • 7.2: Abbott Laboratories
  • 7.3: Amgen
  • 7.4: AstraZeneca
  • 7.5: Bristol-Myers Squibb
  • 7.6: Castle Biosciences
  • 7.7: Daiichi Sankyo
  • 7.8: DAMAE Medical
  • 7.9: DermTech
  • 7.10: F. Hoffmann-La Roche